ROKIT HEALTHCARE is a leading regenerative medicine biotechnology company based in South Korea. We are committed to pioneering medical treatments based on the principles of 3D bioprinting and autologous stem cell use to regenerate and restore functions of human tissues and organs.
- ROKIT HEALTHCARE: We develop and supply a technology platform of a bioprinter, bioinks, and protocols to expedite advancement and eventual translation of 3D bioprinting in the operating room.
- Organ Regeneration Platform (O.R.P.): ROKIT Healthcare’s O.R.P. is a global initiative seeking to develop clinically relevant kits of 3D bioprinting-based therapies through a supply of technologies, goods, and services.
- Organ Regenerator : The promise of customized, human tissue printing provides a safe and effective alternative to organ transplantation and existing drug R&D methods.
ROKIT HEALTHCARE is a global healthcare company committed to providing an effective autologous organ regeneration platform using its proprietary biofabrication technologies across all types of applicable diseases in the field of regenerative medicine.
Through a convergence of know-how’s and innovation in the areas of R&D (i.e. 3D bioprinting, autologous stem cell technologies, and human-derived biomaterials), surgical medicine, and regulatory affairs, ROKIT Healthcare believes in supplying customized organ regeneration platform services that will drastically change the way we trust and manage the health of our own body.
Organ Regeneration Platform ROKIT Healthcare
1. Organ Regeneration
2. Human Bio Inks
5. IPSC by mRNA
6. scRNA / Genome
We are working to launch clinical kits composed of the bioprinter, software, biomaterials, and medical operation technologies that doctors can use to treat patients in the operating room. Our focus areas of service range from skin, bone, cartilage, and hair regeneration, to heart patch, retina regeneration, and anti-aging cosmetic development. Beyond these focus areas, we invite open innovation of ideas and expertise to bring to light novel tissue and organ regeneration targets.